Differences Between Sertraline and Citalopram
Both sertraline and citalopram are similarly effective SSRIs with comparable dosing schedules (1-2 week titration intervals), but citalopram carries a critical cardiac safety concern with QT prolongation risk at doses exceeding 40 mg/day, making sertraline the safer choice when higher doses are needed or in patients with cardiac risk factors.
Administration Differences
Dosing Regimens
Sertraline:
- Starting dose: 25-50 mg/day
- Therapeutic range: 50-200 mg/day
- Titration: Increase by smallest available increments at approximately 1-2 week intervals 1
- No maximum dose restrictions based on age alone
Citalopram:
- Starting dose: 10-20 mg/day 2
- Therapeutic range: 20-40 mg/day
- Maximum dose: 40 mg/day (20 mg/day in patients >60 years) 1, 3
- Titration: Similar 1-2 week intervals as sertraline 1
Both medications are shorter-acting SSRIs requiring similar titration schedules, unlike fluoxetine which requires 3-4 week intervals 1.
Side Effect Profile Differences
Discontinuation Syndrome
Sertraline has been specifically associated with discontinuation syndrome (though less than paroxetine), characterized by dizziness, fatigue, nausea, sensory disturbances, and anxiety following missed doses or abrupt cessation 1. Citalopram is notably absent from the list of SSRIs associated with discontinuation syndrome in the guidelines 1.
Cardiac Safety - Critical Distinction
Citalopram poses significant cardiac risk:
- Causes QT prolongation associated with Torsade de Pointes, ventricular tachycardia, and sudden death at daily doses exceeding 40 mg/day 1
- Must be avoided in patients with long QT syndrome 1
- Has particular interaction risk with other QT-prolonging drugs 1
- FDA and EMA have imposed maximum dose restrictions specifically due to QT studies 3
Sertraline does not carry these specific cardiac warnings, though it may interact with drugs metabolized by CYP2D6 1.
Gastrointestinal Effects
Sertraline is associated with higher rates of gastrointestinal side effects, particularly early in treatment:
- Diarrhea/loose stools: 18-24% vs 10-13% for citalopram 4
- Nausea: 21-26% vs 11-23% 4
- This contributes to higher early discontinuation rates with sertraline 5
Citalopram demonstrates better initial tolerability with fewer GI complaints 5.
Sexual Dysfunction
Both medications cause sexual dysfunction, but rates are comparable:
- Ejaculatory failure: 14-17% for sertraline, similar for citalopram 4
- Decreased libido: 6% for sertraline, 2-4% for citalopram 4
Drug Interaction Profile
Citalopram/escitalopram has the least effect on CYP450 isoenzymes compared with other SSRIs and thus has a lower propensity for drug interactions 1. This is a significant advantage.
Sertraline may interact with drugs metabolized by CYP2D6 1, though it has less effect on drug metabolism than fluoxetine or paroxetine 2.
Clinical Decision Algorithm
Choose Sertraline when:
- Higher doses (>40 mg citalopram equivalent) may be needed
- Patient has cardiac risk factors or prolonged QT
- Patient is >60 years old and may require dose escalation
- Patient takes other QT-prolonging medications
Choose Citalopram when:
- Lower doses will suffice (≤40 mg/day, ≤20 mg/day if >60 years)
- Minimizing drug-drug interactions is priority
- Patient has history of poor GI tolerability with other SSRIs
- No cardiac risk factors present
Common Pitfalls:
- Exceeding 40 mg/day citalopram (20 mg/day in elderly) - this is contraindicated due to mortality risk 1, 3
- Failing to obtain baseline ECG in citalopram patients with cardiac risk factors
- Abruptly discontinuing sertraline without taper (higher discontinuation syndrome risk) 1
- Combining citalopram with other QT-prolonging drugs without careful monitoring 1
Both medications require starting at subtherapeutic "test" doses to minimize initial anxiety/agitation, a common early adverse effect of all SSRIs 1.